|
gptkbp:instanceOf
|
gptkb:brand
antidepressant
|
|
gptkbp:activeIngredient
|
gptkb:paroxetine
|
|
gptkbp:approvedBy
|
1991
|
|
gptkbp:ATCCode
|
N06AB05
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
hypersensitivity to paroxetine
|
|
gptkbp:discoveredBy
|
gptkb:Ferrosan
|
|
gptkbp:drugClass
|
selective serotonin reuptake inhibitor
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
|
|
gptkbp:halfLife
|
21 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Seroxat
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:tricyclic_antidepressants
gptkb:warfarin
gptkb:MAO_inhibitors
gptkb:NSAIDs
antipsychotics
antiepileptics
other SSRIs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:marketedAs
|
gptkb:Aropax
gptkb:Paxil
Paroxat
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
1975
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
bleeding
hyponatremia
suicidal thoughts (especially in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
weight gain
sweating
insomnia
drowsiness
dry mouth
sexual dysfunction
withdrawal symptoms
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:withdrawalSyndrome
|
gptkb:discontinuation_syndrome
|
|
gptkbp:bfsParent
|
gptkb:paroxetine
|
|
gptkbp:bfsLayer
|
6
|